Medexus Welcomes Two New Board Members

Harmony P. Garges MD MPH and Menassie Taddese MBA appointed to Medexus’s board of directors

Appointments bolster Medexus board’s medical and financial expertise, particularly in the United States

TORONTO and CHICAGO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) is pleased to welcome Harmony P. Garges MD MPH, Chief Medical Officer of ViiV Healthcare, and Menassie Taddese MBA, former executive at Pfizer and Viatris, to the Medexus board of directors.

“We are very pleased to welcome Harmony and Menassie, two experienced professionals whose skills, experience, and expertise will serve to diversify and supplement those of the current members of our board,” commented Benoit Gravel, Chair of the Compensation, Corporate Governance, and Nominating Committee of the Board of Directors.

Ken d’Entremont, Chief Executive Officer of Medexus, added, “We are thrilled to have Harmony and Menassie join our board. As we continue to evaluate new opportunities to grow our business, strengthening our team remains a priority. Harmony’s significant experience leading medical affairs and medical regulatory matters and Menassie’s strong management experience and expertise in corporate finance will undoubtedly be assets as we grow our business organically and engage in new business and corporate development initiatives.”

Dr Garges and Mr Taddese were elected to fill two newly created directorships with effect as of February 6, 2023 and will initially serve until the next annual meeting of Medexus shareholders. For more information about the Medexus board of directors, see the Governance section of Medexus’s corporate website.

About Dr Garges and Mr Taddese

Harmony P. Garges MD MPH brings 18 years of multinational pharmaceutical leadership experience in the United States and the UK to the Medexus board. Dr Garges has served as Chief Medical Officer of ViiV Healthcare since August 2019. In this role, Dr Garges is accountable for all aspects of human safety and medical governance and for the global medical affairs strategy and execution for the company. Dr Garges joined ViiV Healthcare in 2016 after spending over a decade at GSK in various leadership roles across R&D, pharmacovigilance, and medical affairs. During her career, Dr Garges has provided medical leadership for over a dozen new drug applications and new product launches.